Abstract Library

#4615 Dosimetry, efficacy and safety of radiolabelled somatostatin receptor antagonist in patients with metastatic pheochromocytoma or paraganglioma

Introduction: Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with a heterogenous phenotype and a variable treatment response. The SSTR antagonist [177Lu]Lu177Lu-DOTA-JR11 (177Lu-JR11) offers potentially increased tumour doses than standard radioligand therapy (RLT) with [177Lu]Lu-DOTA-TOC (177Lu-TOC).

Conference:

Presenting Author: Lider S

Authors: Lider Burciulescu S, Schmidt F, McDougall L, Bernhardt P, Mushaweh A,

Keywords: Metastatic PPGL, radioligand therapy, somatostatin receptor antagonist, dosimetry,

#4498 Quality of life outcome after each cycle in NET patients receiving peptide receptor radionuclide therapy (PRRT)

Introduction: Quality of Life (QoL) Questionnaire GI NET21 was developed specifically for neuroendocrine tumours (NET). A significant proportion of all patients with GEP-NETs will ultimately present with a wide variety of NET-related symptoms such as skin flushing, diarrhoea and pain as well as disease related worries that can reduce QoL. Peptide receptor radionuclide therapy (PRRT) is an established treatment in NETs and has been shown to extend survival. However, QoL data post PRRT is still somewhat limited.

Conference:

Presenting Author: Vito I

Authors: Vito I, Santillan N, Davis N, Navalkissoor S,

Keywords: Lu-177-DOTATATE, PRRT, Quality of Life,

#4451 The management of well-differentiated gastroenteropancreatic neuroendocrine tumours in a tertiary centre – The contribution of radionuclide therapy

Introduction: Neuroendocrine tumours represent a heterogenous group of tumours with different locations, whose management is necessary to identify specific parameters that determine the choice of optimal treatment.

Conference:

Presenting Author: Oana Stefania S

Authors: Oana Stefania S, Corin B, Victoria V, Sofia L,

Keywords: GEP-NET, well-differentiated, PRRT, Cromogranine A, Serotonin, RECIST 1.1,

#4022 Immediate and sustained response of hypoglycaemia to Streptozotocin-based chemotherapy in metastatic Insulinoma: A case report

Introduction: Hypoglycaemia due to insulin production from insulinomas can be challenging to manage. The evidence base for systemic treatment selection is small.

Conference:

Presenting Author:

Authors: Sherriff D, Flanagan D,

Keywords: insulinoma, hypoglycaemia, streptozotocin,

#3827 Prevalence of Clonal Hematopoiesis (CH) in neuroendocrine tumor (NET) patients prior to Lutetium 177 dotatate therapy (Lu177) and the risk of cytopenia – A prospective study of 37 patients

Introduction: Lu177 has shown efficacy in advanced NET but with significant hematologic toxicity, including therapy-related myeloid neoplasm (t-MN). CH is defined by acquisition of somatic mutations in hematopoietic stem cells with potential for expansion over time.

Conference:

Presenting Author: Sonbol M

Authors: Sonbol M, Kusne Y, Lasho T, Elsabbagh Z, Mangaonkar A,

Keywords: clonal hematopoiesis, neuroendocrine, PRRT, Lu177, t-MN, CHIP,